Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29430721 | 1.00 | NOTUM (0.54) | NOTUMCA1CA2CA12CA7 | |
| SCHEMBL2483007 | 0.87 | NOTUM (0.50) | NOTUMCA1CA2CA12CA7 | |
| SCHEMBL8148281 | 0.84 | CA1 (0.52) | CA1CA2CA12CA7CA9 | |
| SCHEMBL2421850 | 0.83 | CA12 (0.51) | CA1CA2CA12CA7CA9 | |
| SCHEMBL2818982 | 0.81 | KDM4E (0.53) | CA1CA2CA12CA7CA9 | |
| SCHEMBL536163 | 0.81 | S1PR3 (0.51) | NOTUMCA1CA2CA12CA7 | |
| SCHEMBL2427132 | 0.81 | CA1 (0.62) | CA1CA2CA12CA7CA9 | |
| SCHEMBL842203 | 0.81 | CYP11B1 (0.42) | ALDH1A1HSD17B10MAPTHPGDMEN1 | |
| SCHEMBL105391 | 0.80 | ALDH1A1 (0.59) | CA1CA2CA12CA7CA9 | |
| SCHEMBL1275177 | 0.80 | TRPA1 (0.51) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3773573-B1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC INC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12221416-B2 | Antagonists of human integrin α4β7 | MORPHIC THERAPEUTIC, INC. (US) | 2025-02-11 | — | — | US | disclosed |
| US-20240366595-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2024-11-07 | — | — | US | disclosed |
| US-20240294475-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2024-09-05 | — | — | US | disclosed |
| US-12023333-B2 | Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators | Grey Wolf Therapeutics Limited (GB) | 2024-07-02 | — | — | US | disclosed |
| WO-2024086246-A2 | 2-SUBSTITUTED 3,4 A, 5, 7, 8, 8 A-HEXAHYDRO-4H-THIOP YRANO [4,3- DJPYRIMIDIN-4-ONES FOR WOUND TREATMENT | Eluciderm Inc. (US) | 2024-04-25 | — | — | WO | disclosed |
| WO-2024086246-A2 | 2-SUBSTITUTED 3,4 A, 5, 7, 8, 8 A-HEXAHYDRO-4H-THIOP YRANO [4,3- DJPYRIMIDIN-4-ONES FOR WOUND TREATMENT | Eluciderm Inc. (US) | 2024-04-25 | — | — | WO | disclosed |
| WO-2024059186-A1 | N-((ISOQUINOLIN-6-YL)METHYL)-1H-PYRAZOLE-4-CARBOXAMID DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS FOR THE TREATMENT OF HEREDITARY ANGIOEDEMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-03-21 | — | — | WO | disclosed |
| US-20220347176-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2022-11-03 | — | — | US | disclosed |
| US-20220340529-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2022-10-27 | — | — | US | disclosed |
| EP-1893597-B1 | AMPA RECEPTOR POTENTIATORS | LILLY CO ELI (US) | 2008-11-12 | — | — | EP | disclosed |
| US-7393868-B2 | AMPA receptor potentiators | ELI LILLY AND COMPANY (US) | 2008-07-01 | — | — | US | disclosed |
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | disclosed |
| EP-1893597-A2 | AMPA RECEPTOR POTENTIATORS | ELI LILLY AND COMPANY (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2008024978-A2 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024978-A2 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| US-20070142441-A1 | AMPA receptor potentiators | ELI LILLY AND COMPANY | 2007-06-21 | — | — | US | disclosed |
| WO-2006132811-A2 | AMPA RECEPTOR POTENTIATORS | ELI LILLY AND COMPANY (US) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366595-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | CHP1, ERAP1, QSOX1 | NOTUM 4687/4885CA1 841/4885CA2 596/4885 |
| US-20220347176-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | ERAP1, CHP1, QSOX1 | NOTUM 4676/4885CA1 861/4885CA2 479/4885 |
| US-20070142441-A1 | AMPA receptor potentiators | GABRE, GRIN1, GRIK2 | NOTUM 2479/4885CA1 522/4885CA2 625/4885 |
| US-12221416-B2 | Antagonists of human integrin α4β7 | ITGB7, ITGB4, ITGA4 | NOTUM 4552/4885CA1 4288/4885CA2 4364/4885 |
| US-12023333-B2 | Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators | ERAP1, CHP1, QSOX1 | NOTUM 4646/4885CA1 786/4885CA2 453/4885 |
| US-20220340529-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | ITGB7, ITGB4, ITGA4 | NOTUM 4273/4885CA1 3535/4885CA2 3512/4885 |
| US-20240294475-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | ITGB7, ITGB4, ITGA4 | NOTUM 4273/4885CA1 3535/4885CA2 3512/4885 |
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | MKI67, CCNB1, RB1 | NOTUM 4762/4885CA1 4138/4885CA2 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.